Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DIMEvAR

Financiado

Cerrado

Impact of medical drugs on the evolution of human microbiome function and antimi...

Impact of medical drugs on the evolution of human microbiome function and antimicrobial resistance development The human gastrointestinal tract harbors trillions of microbes, known as the gut microbiota. This microbial community helps modulating developmental, immunological, and metabolic functions of the human host and it plays an importa... ver más

31/03/2024

EMBL

262K€

Presupuesto del proyecto: 262K€

Líder del proyecto

EUROPEAN MOLECULAR BIOLOGY LABORATORY No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-03-31

MSCA-IF-2020: Individual Fellowships

I+D

Cerrada hace 4 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

EMBL

262.21K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EvoGutHealth Evolution of gut associated microbial communities and its fu... 2M€ Cerrado

SAF2012-31187 INTERACCION DEL MICROBIOMA Y EL VIROMA DEL INTESTINO HUMANO... 380K€ Cerrado

BiPMeM Mechanistic study of gut microbial biotransformation reactio... 174K€ Cerrado

gutMAP Gut microbiome-mediated activities of psychotropic drugs 1M€ Cerrado

GutTransForm Gut microbiota drug biotransformation as a tool to unravel t... 2M€ Cerrado

SAF2014-60234-R ESTUDIO DEL EFECTO PROTECTOR DEL MICROBIOMA FRENTE A INFECCI... 194K€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2021-03-13
Fecha Fin: 2024-03-31

Líder del proyecto

EUROPEAN MOLECULAR BIOLOGY LABORATORY No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 262K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The human gastrointestinal tract harbors trillions of microbes, known as the gut microbiota. This microbial community helps modulating developmental, immunological, and metabolic functions of the human host and it plays an important role in medicinal drug response. Several works showed the bidirectional relationship between the gut microbiota and drugs. Medication modifies microbiome composition both in vitro and in the human gut. Further, commonly used drugs influence the microbiome metabolic functions and increase the abundance of antimicrobial resistance (AMR) genes in human cohort studies, suggesting that non-antibiotic drugs could contribute to the emergence of AMR. At the same time, microbiome-encoded enzymes can metabolize a wide range of medical drugs, participating in both beneficial and adverse effects. Considering that many drugs are used over extended periods of time to treat chronic diseases, long-term exposure to drugs may likely drive microbiome evolution. This could influence and evolve metabolic properties of gut microbes and lead to the emergence of novel AMR. This project aims at better understanding the impact of long-term exposure to medical drugs on human gut microbiome evolution at the phenotypic and metabolic level, the underlying molecular mechanism, and their consequences in vivo. Based on previous data and in analogy to well-understood antibiotics, I hypothesize that non-antibiotic drugs might induce stress-triggered microbial evolution. The project follows three specific objectives: (i) Quantify the impact of drug-induced evolution on microbiome metabolism and antibiotic sensitivity; (ii) Determine the role of bacterial stress responses in microbiome evolution; (iii) Assess drug-induced microbiome evolution using gnotobiotic mouse models. If successful, this work will reveal the molecular mechanisms underlying microbiome-drug interactions and pave the way for their rational modulation to improve current and future drug therapies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores